Search

Your search keyword '"Xia, Zhong-Jun"' showing total 339 results
Start Over Author "Xia, Zhong-Jun"
339 results on '"Xia, Zhong-Jun"'

2. A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma

Author

Wang, Hua, Fu, Bi-bo, Wuxiao, Zhi-jun, Li, Ya-jun, Huang, Li, Ma, Jie, Zhai, Zhi-min, Guo, Jing, Wu, Yuan-bin, Xu, Zhen-shu, Feng, Jia, Zhou, Sheng-sheng, Chen, Ting-ting, Chen, Xing-gui, Li, Guo-wei, Liu, Ting-zhi, Huang, Hai-bin, Zheng, Run-hui, Li, Yong-hua, Tao, Hong-fang, Zi, Fu-ming, Wu, Fan, Wang, Juan, Zeng, Hui, Fu, Cai-bo, Gale, Robert Peter, Xia, Zhong-jun, and Liang, Yang

Published
2022
Full Text
View/download PDF

3. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma

Author

Tian, Xiao-Peng, Ma, Shu-Yun, Young, Ken H., Ong, Choon Kiat, Liu, Yan-Hui, Li, Zhi-Hua, Zhai, Qiong-Li, Huang, Hui-Qiang, Lin, Tong-Yu, Li, Zhi-Ming, Xia, Zhong-Jun, Zhong, Li-Ye, Rao, Hui-Lan, Li, Mei, Cai, Jun, Zhang, Yu-Chen, Zhang, Fen, Su, Ning, Li, Peng-Fei, Zhu, Feng, Xu-Monette, Zijun Y., Wong, Esther Kam Yin, Ha, Jeslin Chian Hung, Khoo, Lay Poh, Ai, Le, Cheng, Run-Fen, Lim, Jing Quan, de Mel, Sanjay, Ng, Siok-Bian, Lim, Soon Thye, and Cai, Qing-Qing

Published
2021
Full Text
View/download PDF

4. A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study

Author

Tian, Xiao-Peng, Xie, Dan, Huang, Wei-Juan, Ma, Shu-Yun, Wang, Liang, Liu, Yan-Hui, Zhang, Xi, Huang, Hui-Qiang, Lin, Tong-Yu, Rao, Hui-Lan, Li, Mei, Liu, Fang, Zhang, Fen, Zhong, Li-Ye, Liang, Li, Lan, Xiao-Liang, Li, Juan, Liao, Bing, Li, Zhi-Hua, Tang, Qiong-Lan, Liang, Qiong, Shao, Chun-Kui, Zhai, Qiong-Li, Cheng, Run-Fen, Sun, Qi, Ru, Kun, Gu, Xia, Lin, Xi-Na, Yi, Kun, Shuang, Yue-Rong, Chen, Xiao-Dong, Dong, Wei, Sang, Wei, Sun, Cai, Liu, Hui, Zhu, Zhi-Gang, Rao, Jun, Guo, Qiao-Nan, Zhou, Ying, Meng, Xiang-Ling, Zhu, Yong, Hu, Chang-Lu, Jiang, Yi-Rong, Zhang, Ying, Gao, Hong-Yi, He, Wen-Jun, Xia, Zhong-Jun, Pan, Xue-Yi, Lan, Hai, Li, Guo-Wei, Liu, Lu, Bao, Hui-Zheng, Song, Li-Yan, Kang, Tie-Bang, and Cai, Qing-Qing

Published
2020
Full Text
View/download PDF

5. Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma

Author

Tian, Xiao-Peng, Huang, Wei-Juan, Huang, Hui-Qiang, Liu, Yan-Hui, Wang, Liang, Zhang, Xi, Lin, Tong-Yu, Rao, Hui-Lan, Li, Mei, Liu, Fang, Zhang, Fen, Zhong, Li-Ye, Liang, Li, Lan, Xiao-Liang, Li, Juan, Liao, Bing, Li, Zhi-Hua, Tang, Qiong-Lan, Liang, Qiong, Shao, Chun-Kui, Zhai, Qiong-Li, Cheng, Run-Fen, Sun, Qi, Ru, Kun, Gu, Xia, Lin, Xi-Na, Yi, Kun, Shuang, Yue-Rong, Chen, Xiao-Dong, Dong, Wei, Sang, Wei, Sun, Cai, Liu, Hui, Zhu, Zhi-Gang, Rao, Jun, Guo, Qiao-Nan, Zhou, Ying, Meng, Xiang-Ling, Zhu, Yong, Hu, Chang-Lu, Jiang, Yi-Rong, Zhang, Ying, Gao, Hong-Yi, He, Wen-Jun, Xia, Zhong-Jun, Wu, Cheng-Lei, Zhang, Mei-Yin, Wang, Hui-Yun, Xie, Dan, and Cai, Qing-Qing

Published
2019
Full Text
View/download PDF

6. P949: COMBINATION GA AND MPR VULNERABILITY SCORING TOOLS EFFECTIVELY IMPROVE THE ABILITY TO IDENTIFY THE FRAIL ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

Author

Lu, Minqiu, primary, Peng, Liu, additional, Zhuang, Junling, additional, Zhang, Mei, additional, Xia, Zhong-Jun, additional, LI, Zhenling, additional, Jing, Hongmei, additional, Dong, Fei, additional, Chen, Wen-Ming, additional, Wu, Yin, additional, Zhou, Hebing, additional, Gong, Yu-Ping, additional, Fu, Rong, additional, Huang, Wen-Rong, additional, Chu, Bin, additional, Wang, Yutong, additional, Zhang, Yong-Qing, additional, Kai, Sun, additional, and Bao, LI, additional

Published
2023
Full Text
View/download PDF

7. Supplementary Figure S19 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma

Author

Tian, Xiao-Peng, primary, Su, Ning, primary, Wang, Liang, primary, Huang, Wei-Juan, primary, Liu, Yan-Hui, primary, Zhang, Xi, primary, Huang, Hui-Qiang, primary, Lin, Tong-Yu, primary, Ma, Shu-Yun, primary, Rao, Hui-Lan, primary, Li, Mei, primary, Liu, Fang, primary, Zhang, Fen, primary, Zhong, Li-Ye, primary, Liang, Li, primary, Lan, Xiao-Liang, primary, Li, Juan, primary, Liao, Bing, primary, Li, Zhi-Hua, primary, Tang, Qiong-Lan, primary, Liang, Qiong, primary, Shao, Chun-Kui, primary, Zhai, Qiong-Li, primary, Cheng, Run-Fen, primary, Sun, Qi, primary, Ru, Kun, primary, Gu, Xia, primary, Lin, Xi-Na, primary, Yi, Kun, primary, Shuang, Yue-Rong, primary, Chen, Xiao-Dong, primary, Dong, Wei, primary, Sun, Cai, primary, Sang, Wei, primary, Liu, Hui, primary, Zhu, Zhi-Gang, primary, Rao, Jun, primary, Guo, Qiao-Nan, primary, Zhou, Ying, primary, Meng, Xiang-Ling, primary, Zhu, Yong, primary, Hu, Chang-Lu, primary, Jiang, Yi-Rong, primary, Zhang, Ying, primary, Gao, Hong-Yi, primary, He, Wen-Jun, primary, Xia, Zhong-Jun, primary, Pan, Xue-Yi, primary, Hai, Lan, primary, Li, Guo-Wei, primary, Song, Li-Yan, primary, Kang, Tie-Bang, primary, Xie, Dan, primary, and Cai, Qing-Qing, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table S3 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma

Author

Tian, Xiao-Peng, primary, Su, Ning, primary, Wang, Liang, primary, Huang, Wei-Juan, primary, Liu, Yan-Hui, primary, Zhang, Xi, primary, Huang, Hui-Qiang, primary, Lin, Tong-Yu, primary, Ma, Shu-Yun, primary, Rao, Hui-Lan, primary, Li, Mei, primary, Liu, Fang, primary, Zhang, Fen, primary, Zhong, Li-Ye, primary, Liang, Li, primary, Lan, Xiao-Liang, primary, Li, Juan, primary, Liao, Bing, primary, Li, Zhi-Hua, primary, Tang, Qiong-Lan, primary, Liang, Qiong, primary, Shao, Chun-Kui, primary, Zhai, Qiong-Li, primary, Cheng, Run-Fen, primary, Sun, Qi, primary, Ru, Kun, primary, Gu, Xia, primary, Lin, Xi-Na, primary, Yi, Kun, primary, Shuang, Yue-Rong, primary, Chen, Xiao-Dong, primary, Dong, Wei, primary, Sun, Cai, primary, Sang, Wei, primary, Liu, Hui, primary, Zhu, Zhi-Gang, primary, Rao, Jun, primary, Guo, Qiao-Nan, primary, Zhou, Ying, primary, Meng, Xiang-Ling, primary, Zhu, Yong, primary, Hu, Chang-Lu, primary, Jiang, Yi-Rong, primary, Zhang, Ying, primary, Gao, Hong-Yi, primary, He, Wen-Jun, primary, Xia, Zhong-Jun, primary, Pan, Xue-Yi, primary, Hai, Lan, primary, Li, Guo-Wei, primary, Song, Li-Yan, primary, Kang, Tie-Bang, primary, Xie, Dan, primary, and Cai, Qing-Qing, primary

Published
2023
Full Text
View/download PDF

10. Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma

Author

Tian, Xiao-Peng, primary, Zhang, Yu-Chen, additional, Lin, Ning-Jing, additional, Wang, Liang, additional, Li, Zhi-Hua, additional, Guo, Han-Guo, additional, Ma, Shu-Yun, additional, An, Ming-Jie, additional, Yang, Jing, additional, Hong, Yu-Heng, additional, Wang, Xian-Huo, additional, Zhou, Hui, additional, Li, Ya-Jun, additional, Rao, Hui-Lan, additional, Li, Mei, additional, Hu, Shao-Xuan, additional, Lin, Tong-Yu, additional, Li, Zhi-Ming, additional, Huang, He, additional, Liang, Yang, additional, Xia, Zhong-Jun, additional, Lv, Yue, additional, Liu, Yu-Ying, additional, Duan, Zhao-Hui, additional, Chen, Qing-Yu, additional, Wang, Jin-Ni, additional, Cai, Jun, additional, Xie, Ying, additional, Ong, Choon-Kiat, additional, Liu, Fang, additional, Liu, Yan-yan, additional, Yan, Zheng, additional, Huang, Liang, additional, Tao, Rong, additional, Li, Wen-Yu, additional, Huang, Hui-Qiang, additional, and Cai, Qing-Qing, additional

Published
2023
Full Text
View/download PDF

26. Combination of PD‐1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second‐line therapy for relapsed/refractory classical Hodgkin lymphoma

Author

Zhang, Yu‐Chen, primary, Wang, Jin‐Ni, additional, Ma, Shu‐Yun, additional, Cai, Jun, additional, Su, Ning, additional, Huang, Hui‐Qiang, additional, Li, Zhi‐Ming, additional, Xia, Zhong‐Jun, additional, Huang, He, additional, Liu, Pan‐Pan, additional, Xia, Yi, additional, and Cai, Qing-Qing, additional

Published
2021
Full Text
View/download PDF

35. A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma

Author

Tian, Xiao-Peng, primary, Su, Ning, additional, Wang, Liang, additional, Huang, Wei-Juan, additional, Liu, Yan-Hui, additional, Zhang, Xi, additional, Huang, Hui-Qiang, additional, Lin, Tong-Yu, additional, Ma, Shu-Yun, additional, Rao, Hui-Lan, additional, Li, Mei, additional, Liu, Fang, additional, Zhang, Fen, additional, Zhong, Li-Ye, additional, Liang, Li, additional, Lan, Xiao-Liang, additional, Li, Juan, additional, Liao, Bing, additional, Li, Zhi-Hua, additional, Tang, Qiong-Lan, additional, Liang, Qiong, additional, Shao, Chun-Kui, additional, Zhai, Qiong-Li, additional, Cheng, Run-Fen, additional, Sun, Qi, additional, Ru, Kun, additional, Gu, Xia, additional, Lin, Xi-Na, additional, Yi, Kun, additional, Shuang, Yue-Rong, additional, Chen, Xiao-Dong, additional, Dong, Wei, additional, Sun, Cai, additional, Sang, Wei, additional, Liu, Hui, additional, Zhu, Zhi-Gang, additional, Rao, Jun, additional, Guo, Qiao-Nan, additional, Zhou, Ying, additional, Meng, Xiang-Ling, additional, Zhu, Yong, additional, Hu, Chang-Lu, additional, Jiang, Yi-Rong, additional, Zhang, Ying, additional, Gao, Hong-Yi, additional, He, Wen-Jun, additional, Xia, Zhong-Jun, additional, Pan, Xue-Yi, additional, Hai, Lan, additional, Li, Guo-Wei, additional, Song, Li-Yan, additional, Kang, Tie-Bang, additional, Xie, Dan, additional, and Cai, Qing-Qing, additional

Published
2020
Full Text
View/download PDF

37. BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T‐cell lymphoblastic lymphoma

Author

Tian, Xiao‐Peng, primary, Cai, Jun, additional, Ma, Shu‐Yun, additional, Fang, Yu, additional, Huang, Hui‐Qiang, additional, Lin, Tong‐Yu, additional, Rao, Hui‐Lan, additional, Li, Mei, additional, Xia, Zhong‐Jun, additional, Kang, Tie‐Bang, additional, Xie, Dan, additional, and Cai, Qing‐Qing, additional

Published
2020
Full Text
View/download PDF

40. Combination of PD‐1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second‐line therapy for relapsed/refractory classical Hodgkin lymphoma.

Author

Zhang, Yu‐Chen, Wang, Jin‐Ni, Ma, Shu‐Yun, Cai, Jun, Su, Ning, Huang, Hui‐Qiang, Li, Zhi‐Ming, Xia, Zhong‐Jun, Huang, He, Liu, Pan‐Pan, Xia, Yi, and Cai, Qing-Qing

Subjects
HODGKIN'S disease, PROGRAMMED cell death 1 receptors, VINORELBINE, POSITRON emission tomography, DOXORUBICIN, ANAPLASTIC lymphoma kinase
Abstract

Summary: Patients with classical Hodgkin lymphoma (cHL) who do not achieve complete remission (CR) after second‐line chemotherapy have poor clinical outcomes. Besides, conventional salvage chemotherapy regimens have an unsatisfactory CR rate. The present retrospective study reports the efficacy and toxicity of the GVD (gemcitabine, vinorelbine, liposomal doxorubicin) regimen with or without programmed cell death 1 (PD‐1) inhibitor for patients with cHL who failed first‐line treatment. A total of 103 patients with cHL (GVD+PD‐1 group, n = 27; GVD group, n = 76) with response assessment based on positron emission tomography were included. The GVD+PD‐1 group tended to have a higher CR rate than GVD group (85·2% vs. 65·8%, P = 0·057) and had a better event‐free survival (EFS) (P = 0·034). Subgroup analysis showed that patients with low‐risk second‐line International Prognostic Score might benefit from the addition of PD‐1 inhibitor (GVD+PD‐1 vs. GVD, 100·0% vs. 64·7%, P = 0·028) and had better EFS than GVD alone (P = 0·016). Further analysis demonstrated that PD‐1 consolidation therapy might provide an EFS benefit (P = 0·007). The toxicity of the GVD+PD‐1 regimen was comparable to the GVD regimen, except for higher rates of hypothyroidism and autoimmune pneumonitis, which were manageable. In conclusion, combining a PD‐1 inhibitor with a GVD regimen could be a potentially effective second‐line therapy for patients with cHL. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: A matched case-control analysis in a single institution

Author

Li Ya-Jun, Li Zhi-Ming, Rao Hui-Lan, Xia Yi, Huang Hui-Qiang, Xia Zhong-Jun, Li Su, Li Wen-Yu, and Jiang Wen-Qi

Subjects
Diffuse large B-cell lymphoma, CD20-negative, Clinicopathologic features, HIV-negative, Medicine
Abstract

Abstract Background HIV-negative, CD20-negative de novo diffuse large B-cell lymphoma (DLBCL) patients has rarely been reported. To elucidate the nature of this entity, we retrospectively reviewed the data of 1,456 consecutive de novo DLBCL patients who were treated at Sun Yat-Sen University Cancer Center between January 1999 and March 2011. Methods The pathologic characteristics of CD20-negative patients, clinical features, response to initial treatment, and outcomes of 28 patients with available clinical data (n = 21) were reviewed. Then, a matched case-control (1:3) analysis was performed to compare patients with CD20-negative and -positive DLBCL. Results The median age of the 28 CD20-negative DLBCL patients was 48 years, with a male-female ratio of 20:8. Seventeen of 22 (77.3%) CD20-negative DLBCL cases were of the non-germinal centre B-cell (non-GCB) subtype. High Ki67 expression (≥80%), an index of cell proliferation, was demonstrated in 17 of 24 (70.8%) cases. Extranodal involvement (≥ 1 site) was observed in 76.2% of the patients. Following initial therapy, 9 of 21 (42.9%) cases achieved complete remission, 4 (19%) achieved partial remission, 1 (4.8%) had stable disease, and 7 (33.3%) had disease progression. The median overall survival was 23 months. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 30.5% and 35%, respectively. A matched case-control analysis showed that patients with CD20-negative and -positive DLBCL did not exhibit a statistically significant difference with respect to the main clinical characteristics (except extranodal involvement), whereas the patients with CD20-positive DLBCL had a better survival outcome with 3-year PFS (P = 0.008) and OS (P = 0.008) rates of 52% and 74.1%, respectively. Conclusions This study suggests that HIV-negative, CD20-negative de novo DLBCL patients have a higher proportion of non-GCB subtype, a higher proliferation index, more frequent extranodal involvement, a poorer response, and a poorer prognosis to conventional treatment compared to patients with CD20-positive DLBCL. Further studies are warranted to investigate new target and optimal therapy of CD20-negative de novo DLBCL.

Published
2012
Full Text
View/download PDF

42. Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China

Author

Li, Jing, primary, Bao, Li, additional, Xia, Zhong-jun, additional, Wang, Sili, additional, Zhou, Xin, additional, Ding, Kaiyang, additional, Zhang, Wenhao, additional, Yang, Wei, additional, Li, Bingzong, additional, Fu, Zhengzheng, additional, Chen, Bing, additional, Hua, Luoming, additional, Wang, Liang, additional, Jun, Luo, additional, Yang, Yang, additional, Xu, Tianhong, additional, Wang, Weida, additional, Huang, Yun, additional, Wu, Guolin, additional, and Liu, Peng, additional

Published
2019
Full Text
View/download PDF

43. The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China

Author

Li, Jing, primary, Bao, Li, additional, Xia, Zhong-jun, additional, Ding, Kaiyang, additional, Li, Bingzong, additional, Chen, Bing, additional, Fu, Zhengzheng, additional, Wang, Sili, additional, Zhang, Wenhao, additional, Zhou, Xin, additional, Hua, Luoming, additional, Yang, Wei, additional, Jun, Luo, additional, Wang, Liang, additional, Xu, Tianhong, additional, Yang, Yang, additional, Wang, Weida, additional, Wu, Guolin, additional, Huang, Yun, additional, and Liu, Peng, additional

Published
2019
Full Text
View/download PDF

44. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma

Author

Xia Zhong-jun, Sun Xiao-fei, Huang Hui-qiang, Jiang Wen-qi, Zhang Dong-shen, Luo Hui-yan, Xu Rui-hua, Wang Feng, and Guan Zhong-zhen

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Hepatitis B virus (HBV) infection in diffuse large B-cell lymphoma (DLBCL) patients is a common complication in China. However, the clinical relevance of HBV infection with respect to DLBCL disease stages and patient survival remains unclear. The main objective of the current study was to analyze the clinical features and to evaluate the prognostic factors of HBV infection in DLBCL patients. Methods In this retrospective study, DLBCL patients were divided into two groups as HBsAg-positive (n = 81) and HBsAg-negative (n = 181) patients. The HBsAg-positive patients were further divided into two subgroups based on their hepatic function during chemotherapy. Various statistical analyses were used to determine the significance of the relevant clinical parameters. Results Compared with the HBsAg-negative group, the HBsAg-positive DLBCL group displayed a younger median onset age (46 year vs 51), more advanced stage at grade III/IV (58% vs 42%, p = 0.016), and more frequent hepatic dysfunction before (21% vs 5.5%, p < 0.001) and during (49.4% vs 16.6%, p < 0.001) chemotherapy. Female DLBCL patients exhibited a higher frequency of HBsAg positivity (p = 0.006). However, in both groups the median overall survival (OS) duration (55.8 vs 66.8 months) and response rates (91% vs 90.4%) were similar. In the HBsAg-positive DLBCL group, the poor prognostic factors were advanced stage (p < 0.001) and hepatic dysfunction during chemotherapy (p = 0.02). The OS of HBsAg-positive patients with hepatic dysfunction during chemotherapy was significantly shorter than those without liver dysfunction (p = 0.016), and the OS rates at 3 years were 48% and 72%, respectively. The use of rituximab did not increase the rates of liver dysfunction in HBsAg-positive DLBCL patients. Conclusion Compared with HBsAg-negative patients, the HBsAg-positive DLBCL patients had earlier onset and more advanced stage. The disease stage and hepatic dysfunction during chemotherapy and were two significant prognostic factors in the HBsAg-positive DLBCL patients. This study suggests that prophylactic treatment of HBV may be of great importance in the cases of HBsAg-positive patients.

Published
2008
Full Text
View/download PDF

45. MOESM2 of IL-2RÎą up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma

Author

Wang, Liang, Bi, Xi-Wen, Zhu, Yu-Jia, He, Ying-Zhi, Lai, Qiu-Yu, Xia, Zhong-Jun, and Cai, Qing-Qing

Abstract

Additional file 2: Figure S2. Positron emission tomography-computed tomography of a 42-year-old man with refractory NKTCL before and after treatment with anti-IL-2RÎą antibody (basiliximab) and pegaspargase. Before treatment, diffuse infiltration of lymphoma with high metabolic activity was observed (right panel). After two cycles of treatment, partial remission was observed (left panel).

Published
2018
Full Text
View/download PDF

46. Predictive Value of a CpG Methylation Classifier for Relapse in Adults with T-Cell Lymphoblastic Lymphoma: A Multicentre Study

Author

Tian, Xiao-Peng, primary, Huang, Wei-Juan, additional, Wang, Liang, additional, Su, Ning, additional, Liu, Yan-Hui, additional, Zhang, Xi, additional, Huang, Hui-Qiang, additional, Lin, Tong-Yu, additional, Rao, Hui-Lan, additional, Li, Mei, additional, Liu, Fang, additional, Zhang, Fen, additional, Zhong, Li-Ye, additional, Liang, Li, additional, Lan, Xiao-Liang, additional, Li, Juan, additional, Liao, Bing, additional, Li, Zhi-Hua, additional, Tang, Qiong-Lan, additional, Liang, Qiong, additional, Shao, Chun-Kui, additional, Zhai, Qiong-Li, additional, Cheng, Run-Fen, additional, Sun, Qi, additional, Ruan, Kun, additional, Ru, Kun, additional, Gu, Xia, additional, Lin, Xi-Na, additional, Yi, Kun, additional, Shuang, Yue-Rong, additional, Chen, Xiao-Dong, additional, Dong, Wei, additional, Sang, Wei, additional, Sun, Cai, additional, Liu, Hui, additional, Zhu, Zhi-Gang, additional, Rao, Jun, additional, Guo, Qiao-Nan, additional, Zhou, Ying, additional, Meng, Xiang-Ling, additional, Zhu, Yong, additional, Hu, Chang-Lu, additional, Jiang, Yi-Rong, additional, Zhang, Ying, additional, Gao, Hong-Yi, additional, He, Wen-Jun, additional, Xia, Zhong-Jun, additional, Pan, Xue-Yi, additional, Hai, Lan, additional, Li, Guo-Wei, additional, Song, Li-Yan, additional, Kang, Tie-Bang, additional, Xie, Dan, additional, and Cai, Qing-Qing, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results